Mark Halvorson

Array ( [id] => 14583969 [patent_doc_number] => 20190219593 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-18 [patent_title] => METHOD FOR IDENTIFYING NEOANTIGENS ON CANCER CELLS BY USING XENOANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/243161 [patent_app_country] => US [patent_app_date] => 2019-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9085 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16243161 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16558431 [patent_doc_number] => 20210003580 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-07 [patent_title] => METHODS OF DETECTION AND TREATMENT OF HYPER TRANSCRIPTION DISEASES [patent_app_type] => utility [patent_app_number] => 15/733349 [patent_app_country] => US [patent_app_date] => 2019-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27276 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15733349 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16673145 [patent_doc_number] => 20210061908 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-04 [patent_title] => ANTIBODIES TARGETING, AND OTHER MODULATORS OF, AN IMMUNOGLOBULIN GENE ASSOCIATED WITH RESISTANCE AGAINST ANTI-TUMOUR IMMUNE RESPONSES, AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/957838 [patent_app_country] => US [patent_app_date] => 2019-01-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 62659 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16957838 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16807912 [patent_doc_number] => 20210130465 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => Bispecific Antibody Construct Directed to MUC17 and CD3 [patent_app_type] => utility [patent_app_number] => 16/956797 [patent_app_country] => US [patent_app_date] => 2018-12-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53884 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16956797 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14746765 [patent_doc_number] => 20190256556 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-22 [patent_title] => PURIFICATION OF MULTISPECIFIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/221369 [patent_app_country] => US [patent_app_date] => 2018-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61609 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -57 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16221369 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17697136 [patent_doc_number] => 11370847 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-06-28 [patent_title] => Single domain antibodies directed against intracellular antigens [patent_app_type] => utility [patent_app_number] => 16/195542 [patent_app_country] => US [patent_app_date] => 2018-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 29 [patent_no_of_words] => 36695 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16195542 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14277293 [patent_doc_number] => 20190135931 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-09 [patent_title] => COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/183988 [patent_app_country] => US [patent_app_date] => 2018-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28802 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 201 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16183988 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14685089 [patent_doc_number] => 20190241659 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-08 [patent_title] => BISPECIFIC FUSION POLYPEPTIDES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/184251 [patent_app_country] => US [patent_app_date] => 2018-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26027 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16184251 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13982549 [patent_doc_number] => 20190060432 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-28 [patent_title] => COMPOSITIONS AND METHODS OF IDENTIFYING TUMOR SPECIFIC NEOANTIGENS [patent_app_type] => utility [patent_app_number] => 16/181098 [patent_app_country] => US [patent_app_date] => 2018-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22711 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 130 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16181098 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14213993 [patent_doc_number] => 20190119381 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-25 [patent_title] => FULLY HUMAN ANTIBODIES TO BTLA [patent_app_type] => utility [patent_app_number] => 16/176335 [patent_app_country] => US [patent_app_date] => 2018-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35237 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 124 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16176335 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14216923 [patent_doc_number] => 20190120846 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-25 [patent_title] => CELL SURFACE PROSTATE CANCER ANTIGEN FOR DIAGNOSIS [patent_app_type] => utility [patent_app_number] => 16/175433 [patent_app_country] => US [patent_app_date] => 2018-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16098 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16175433 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14216923 [patent_doc_number] => 20190120846 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-25 [patent_title] => CELL SURFACE PROSTATE CANCER ANTIGEN FOR DIAGNOSIS [patent_app_type] => utility [patent_app_number] => 16/175433 [patent_app_country] => US [patent_app_date] => 2018-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16098 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16175433 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19701527 [patent_doc_number] => 12195536 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-14 [patent_title] => DNA monoclonal antibodies targeting CTLA-4 for the treatment and prevention of cancer [patent_app_type] => utility [patent_app_number] => 16/753870 [patent_app_country] => US [patent_app_date] => 2018-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 26188 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16753870 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16452992 [patent_doc_number] => 20200362418 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-19 [patent_title] => METHOD OF PREDICTION OF TUMOR-DERIVED NEO-PEPTIDE ANTIGENICITY AND/OR IMMUNOGENICITY USING MUTATIONAL SIGNATURE PATTERNS [patent_app_type] => utility [patent_app_number] => 16/652857 [patent_app_country] => US [patent_app_date] => 2018-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3829 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16652857 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16236649 [patent_doc_number] => 20200253883 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-13 [patent_title] => Fusion Proteins Having a Toxin and Cancer Marker, Nanoparticles, and Uses Related Thereto [patent_app_type] => utility [patent_app_number] => 16/651699 [patent_app_country] => US [patent_app_date] => 2018-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13497 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16651699 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14569473 [patent_doc_number] => 20190212343 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-11 [patent_title] => METHODS FOR THE TREATMENT OF DISORDERS RELATED TO PHOSPHORYLATION OF HISTONES [patent_app_type] => utility [patent_app_number] => 16/139521 [patent_app_country] => US [patent_app_date] => 2018-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21551 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16139521 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17541021 [patent_doc_number] => 11306132 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-19 [patent_title] => HLA class II-restricted T cell receptors against mutated RAS [patent_app_type] => utility [patent_app_number] => 16/135231 [patent_app_country] => US [patent_app_date] => 2018-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 18356 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16135231 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16142087 [patent_doc_number] => 10704108 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-07-07 [patent_title] => Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma [patent_app_type] => utility [patent_app_number] => 16/132928 [patent_app_country] => US [patent_app_date] => 2018-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 18 [patent_no_of_words] => 20269 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16132928 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14132377 [patent_doc_number] => 20190100578 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-04 [patent_title] => Anti-Polyubiquitin Antibodies and Methods of Use [patent_app_type] => utility [patent_app_number] => 16/131608 [patent_app_country] => US [patent_app_date] => 2018-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34140 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16131608 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16283794 [patent_doc_number] => 20200277396 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => Treatment Method [patent_app_type] => utility [patent_app_number] => 16/646745 [patent_app_country] => US [patent_app_date] => 2018-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15424 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16646745 [rel_patent_id] =>[rel_patent_doc_number] =>)